NCT05445063View on ClinicalTrials.gov

Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Macular Degeneration
Interventions
BIOLOGICAL

Autologous iPSC-derived RPE

Autologous transplantation of iPSC-derived RPE

Trial Locations (1)

100730

RECRUITING

Beijing Tongren Hospitol,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER